{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-ddpModified.=2019-10-16T20%3A15%3A56.062Z&AnsweringBody.=Department+of+Health+and+Social+Care&min-answer.questionFirstAnswered.=2019-05-15T12%3A39%3A20.147Z&dateTabled=2019-05-07&max-questionFirstAnswered.=2019-10-29T15%3A50%3A45.767Z", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?max-ddpModified.=2019-10-16T20%3A15%3A56.062Z&AnsweringBody.=Department+of+Health+and+Social+Care&min-answer.questionFirstAnswered.=2019-05-15T12%3A39%3A20.147Z&dateTabled=2019-05-07&max-questionFirstAnswered.=2019-10-29T15%3A50%3A45.767Z", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-ddpModified.=2019-10-16T20%3A15%3A56.062Z&AnsweringBody.=Department+of+Health+and+Social+Care&min-answer.questionFirstAnswered.=2019-05-15T12%3A39%3A20.147Z&dateTabled=2019-05-07&_metadata=all&max-questionFirstAnswered.=2019-10-29T15%3A50%3A45.767Z", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&max-ddpModified.=2019-10-16T20%3A15%3A56.062Z&AnsweringBody.=Department+of+Health+and+Social+Care&min-answer.questionFirstAnswered.=2019-05-15T12%3A39%3A20.147Z&dateTabled=2019-05-07&max-questionFirstAnswered.=2019-10-29T15%3A50%3A45.767Z", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-ddpModified.=2019-10-16T20%3A15%3A56.062Z&AnsweringBody.=Department+of+Health+and+Social+Care&min-answer.questionFirstAnswered.=2019-05-15T12%3A39%3A20.147Z&dateTabled=2019-05-07&max-questionFirstAnswered.=2019-10-29T15%3A50%3A45.767Z", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-ddpModified.=2019-10-16T20%3A15%3A56.062Z&AnsweringBody.=Department+of+Health+and+Social+Care&min-answer.questionFirstAnswered.=2019-05-15T12%3A39%3A20.147Z&dateTabled=2019-05-07&max-questionFirstAnswered.=2019-10-29T15%3A50%3A45.767Z", "items" : [{"_about" : "http://data.parliament.uk/resources/1124901", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1124901/answer", "answerText" : {"_value" : "

Departmental officials are in regular contact with colleagues in the National Institute for Health and Care Excellence (NICE) and NHS England about a range of issues, including progress in discussions about a potential managed access agreement for Spinraza (nusinersen). Ministers have also held meetings with Biogen, NICE and NHS England on a number of occasions, at which the availability of Spinraza was discussed.<\/p>

NHS England and NICE have made stakeholders and the public aware of the outcome of its appraisal committee meeting and NICE is now able to recommend the use of Spinraza for National Health Service patients in England, subject to a managed access agreement agreed between NHS England and Biogen. The final appraisal document will be published in due course.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4019", "label" : {"_value" : "Biography information for Baroness Blackwood of North Oxford"} } , "answeringMemberPrinted" : {"_value" : "Baroness Blackwood of North Oxford"} , "dateOfAnswer" : {"_value" : "2019-05-17", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "HL15577"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-05-17T11:07:46.62Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-05-07", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Nusinersen"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government what discussions they have had with (1) NICE, (2) NHS England, and (3) Biogen, on a Managed Access Agreement for Spinal Muscular Atrophy treatment, Spinraza.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3785", "label" : {"_value" : "Biography information for Baroness Thomas of Winchester"} } , "tablingMemberPrinted" : [{"_value" : "Baroness Thomas of Winchester"} ], "uin" : "HL15576"} , {"_about" : "http://data.parliament.uk/resources/1124902", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1124902/answer", "answerText" : {"_value" : "

Departmental officials are in regular contact with colleagues in the National Institute for Health and Care Excellence (NICE) and NHS England about a range of issues, including progress in discussions about a potential managed access agreement for Spinraza (nusinersen). Ministers have also held meetings with Biogen, NICE and NHS England on a number of occasions, at which the availability of Spinraza was discussed.<\/p>

NHS England and NICE have made stakeholders and the public aware of the outcome of its appraisal committee meeting and NICE is now able to recommend the use of Spinraza for National Health Service patients in England, subject to a managed access agreement agreed between NHS England and Biogen. The final appraisal document will be published in due course.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4019", "label" : {"_value" : "Biography information for Baroness Blackwood of North Oxford"} } , "answeringMemberPrinted" : {"_value" : "Baroness Blackwood of North Oxford"} , "dateOfAnswer" : {"_value" : "2019-05-17", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "HL15576"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-05-17T11:07:46.673Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-05-07", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "National Institute for Health and Care Excellence"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government when they estimate that NICE will publish the outcome of the NICE Evaluation Committee meeting held on 6 March.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3785", "label" : {"_value" : "Biography information for Baroness Thomas of Winchester"} } , "tablingMemberPrinted" : [{"_value" : "Baroness Thomas of Winchester"} ], "uin" : "HL15577"} , {"_about" : "http://data.parliament.uk/resources/1124918", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1124918/answer", "answerText" : {"_value" : "

Regular clinical reviews of patients with severe and moderate haemophilia and access to physiotherapy services are specified within the service specification for haemophilia which is available at the following link:<\/p>

https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf<\/a><\/p>

In addition, the Haemophilia Quality Dashboard has a metric specifically in relation to the proportion of severe Haemophilia patients who have had an annual review. Where local commissioning teams are made aware that haemophilia patients do not have access to appropriate care then local action plans will be agreed to rectify this.<\/p>

The service specification for haemophilia currently does not require that haemophilia patients receive tailored dosing of treatment. However, commissioners consider that this would represent good practice. NHS England has supported clinical teams to provide tailored dosing, within the parameters of the agreed commissioning criteria and guidelines, by making a wide range of products available for reimbursement.<\/p>

To date, all licensed and currently marketed products for haemophilia are available for reimbursement. Some products have been limited to Haemophilia Comprehensive Care Centres due to specific requirements for supporting services and expertise (these are products for patients with inhibitors).<\/p>

NHS England wants all patients with lifelong conditions to be engaged in the management of their condition. NHS England, in conjunction with the United Kingdom Haemophilia Centre Doctors\u2019 Organisation (UKHCDO), believes that tools like Haemtrack are useful in achieving this aim. NHS England is aware of evidence that indicates, but does not confirm, that patients who use Haemtrack have better clinical outcomes than patients who do not. NHS England supports UKHCDO via the National Haemophilia Database to provide further data and evidence demonstrating the value and clinical benefits of Haemtrack.<\/p>

The Commercial Medicines Unit has two national framework agreements in place that provide access to recombinant factor VIII (rFVIII) haemophilia products. The one licensed Extended Half Life-Factor VIII product available in the UK has been funded since September 2016 and a significant number of patients are now treated with this product. NHS England and other UK Health Commissioners work closely with clinicians and patient representatives to ensure that the frameworks continue to meet clinical need whilst delivering good value to the National Health Service.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"} } , "answeringMemberConstituency" : {"_value" : "South Ribble"} , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"} , "dateOfAnswer" : {"_value" : "2019-05-15", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "251322"} , {"_value" : "251323"} , {"_value" : "251324"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-05-15T16:14:44.547Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-05-07", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Haemophilia: Medical Treatments"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that haemophilia patients receive (a) appropriate access to physiotherapy, (b) a regular clinical review, and (c) tailored dosing of treatments in accordance with NHS England\u2019s service specification.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"} } , "tablingMemberConstituency" : {"_value" : "Strangford"} , "tablingMemberPrinted" : [{"_value" : "Jim Shannon"} ], "uin" : "251321"} , {"_about" : "http://data.parliament.uk/resources/1124919", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1124919/answer", "answerText" : {"_value" : "

Regular clinical reviews of patients with severe and moderate haemophilia and access to physiotherapy services are specified within the service specification for haemophilia which is available at the following link:<\/p>

https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf<\/a><\/p>

In addition, the Haemophilia Quality Dashboard has a metric specifically in relation to the proportion of severe Haemophilia patients who have had an annual review. Where local commissioning teams are made aware that haemophilia patients do not have access to appropriate care then local action plans will be agreed to rectify this.<\/p>

The service specification for haemophilia currently does not require that haemophilia patients receive tailored dosing of treatment. However, commissioners consider that this would represent good practice. NHS England has supported clinical teams to provide tailored dosing, within the parameters of the agreed commissioning criteria and guidelines, by making a wide range of products available for reimbursement.<\/p>

To date, all licensed and currently marketed products for haemophilia are available for reimbursement. Some products have been limited to Haemophilia Comprehensive Care Centres due to specific requirements for supporting services and expertise (these are products for patients with inhibitors).<\/p>

NHS England wants all patients with lifelong conditions to be engaged in the management of their condition. NHS England, in conjunction with the United Kingdom Haemophilia Centre Doctors\u2019 Organisation (UKHCDO), believes that tools like Haemtrack are useful in achieving this aim. NHS England is aware of evidence that indicates, but does not confirm, that patients who use Haemtrack have better clinical outcomes than patients who do not. NHS England supports UKHCDO via the National Haemophilia Database to provide further data and evidence demonstrating the value and clinical benefits of Haemtrack.<\/p>

The Commercial Medicines Unit has two national framework agreements in place that provide access to recombinant factor VIII (rFVIII) haemophilia products. The one licensed Extended Half Life-Factor VIII product available in the UK has been funded since September 2016 and a significant number of patients are now treated with this product. NHS England and other UK Health Commissioners work closely with clinicians and patient representatives to ensure that the frameworks continue to meet clinical need whilst delivering good value to the National Health Service.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"} } , "answeringMemberConstituency" : {"_value" : "South Ribble"} , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"} , "dateOfAnswer" : {"_value" : "2019-05-15", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "251321"} , {"_value" : "251323"} , {"_value" : "251324"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-05-15T16:14:44.61Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-05-07", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Haemophilia: Medical Treatments"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect of the Commercial Medicines Unit\u2019s national tender framework for factor VIII haemophilia products on patient access to extended half-life medicines.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"} } , "tablingMemberConstituency" : {"_value" : "Strangford"} , "tablingMemberPrinted" : [{"_value" : "Jim Shannon"} ], "uin" : "251322"} , {"_about" : "http://data.parliament.uk/resources/1124920", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1124920/answer", "answerText" : {"_value" : "

Regular clinical reviews of patients with severe and moderate haemophilia and access to physiotherapy services are specified within the service specification for haemophilia which is available at the following link:<\/p>

https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf<\/a><\/p>

In addition, the Haemophilia Quality Dashboard has a metric specifically in relation to the proportion of severe Haemophilia patients who have had an annual review. Where local commissioning teams are made aware that haemophilia patients do not have access to appropriate care then local action plans will be agreed to rectify this.<\/p>

The service specification for haemophilia currently does not require that haemophilia patients receive tailored dosing of treatment. However, commissioners consider that this would represent good practice. NHS England has supported clinical teams to provide tailored dosing, within the parameters of the agreed commissioning criteria and guidelines, by making a wide range of products available for reimbursement.<\/p>

To date, all licensed and currently marketed products for haemophilia are available for reimbursement. Some products have been limited to Haemophilia Comprehensive Care Centres due to specific requirements for supporting services and expertise (these are products for patients with inhibitors).<\/p>

NHS England wants all patients with lifelong conditions to be engaged in the management of their condition. NHS England, in conjunction with the United Kingdom Haemophilia Centre Doctors\u2019 Organisation (UKHCDO), believes that tools like Haemtrack are useful in achieving this aim. NHS England is aware of evidence that indicates, but does not confirm, that patients who use Haemtrack have better clinical outcomes than patients who do not. NHS England supports UKHCDO via the National Haemophilia Database to provide further data and evidence demonstrating the value and clinical benefits of Haemtrack.<\/p>

The Commercial Medicines Unit has two national framework agreements in place that provide access to recombinant factor VIII (rFVIII) haemophilia products. The one licensed Extended Half Life-Factor VIII product available in the UK has been funded since September 2016 and a significant number of patients are now treated with this product. NHS England and other UK Health Commissioners work closely with clinicians and patient representatives to ensure that the frameworks continue to meet clinical need whilst delivering good value to the National Health Service.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"} } , "answeringMemberConstituency" : {"_value" : "South Ribble"} , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"} , "dateOfAnswer" : {"_value" : "2019-05-15", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "251321"} , {"_value" : "251322"} , {"_value" : "251324"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-05-15T16:14:44.657Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-05-07", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Blood Diseases: Medical Treatments"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps he NHS England is taking to ensure that patients with bleeding disorders have adequate access to treatment options that meet individual patient need.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"} } , "tablingMemberConstituency" : {"_value" : "Strangford"} , "tablingMemberPrinted" : [{"_value" : "Jim Shannon"} ], "uin" : "251323"} , {"_about" : "http://data.parliament.uk/resources/1124921", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1124921/answer", "answerText" : {"_value" : "

Regular clinical reviews of patients with severe and moderate haemophilia and access to physiotherapy services are specified within the service specification for haemophilia which is available at the following link:<\/p>

https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf<\/a><\/p>

In addition, the Haemophilia Quality Dashboard has a metric specifically in relation to the proportion of severe Haemophilia patients who have had an annual review. Where local commissioning teams are made aware that haemophilia patients do not have access to appropriate care then local action plans will be agreed to rectify this.<\/p>

The service specification for haemophilia currently does not require that haemophilia patients receive tailored dosing of treatment. However, commissioners consider that this would represent good practice. NHS England has supported clinical teams to provide tailored dosing, within the parameters of the agreed commissioning criteria and guidelines, by making a wide range of products available for reimbursement.<\/p>

To date, all licensed and currently marketed products for haemophilia are available for reimbursement. Some products have been limited to Haemophilia Comprehensive Care Centres due to specific requirements for supporting services and expertise (these are products for patients with inhibitors).<\/p>

NHS England wants all patients with lifelong conditions to be engaged in the management of their condition. NHS England, in conjunction with the United Kingdom Haemophilia Centre Doctors\u2019 Organisation (UKHCDO), believes that tools like Haemtrack are useful in achieving this aim. NHS England is aware of evidence that indicates, but does not confirm, that patients who use Haemtrack have better clinical outcomes than patients who do not. NHS England supports UKHCDO via the National Haemophilia Database to provide further data and evidence demonstrating the value and clinical benefits of Haemtrack.<\/p>

The Commercial Medicines Unit has two national framework agreements in place that provide access to recombinant factor VIII (rFVIII) haemophilia products. The one licensed Extended Half Life-Factor VIII product available in the UK has been funded since September 2016 and a significant number of patients are now treated with this product. NHS England and other UK Health Commissioners work closely with clinicians and patient representatives to ensure that the frameworks continue to meet clinical need whilst delivering good value to the National Health Service.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"} } , "answeringMemberConstituency" : {"_value" : "South Ribble"} , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"} , "dateOfAnswer" : {"_value" : "2019-05-15", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "251321"} , {"_value" : "251322"} , {"_value" : "251323"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-05-15T16:14:44.703Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-05-07", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Haemophilia: Medical Treatments"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether NHS England has made an assessment of the adequacy of the availability of Haemtrack in Haemophilia centres.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"} } , "tablingMemberConstituency" : {"_value" : "Strangford"} , "tablingMemberPrinted" : [{"_value" : "Jim Shannon"} ], "uin" : "251324"} , {"_about" : "http://data.parliament.uk/resources/1124923", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1124923/answer", "answerText" : {"_value" : "

Public Health England does not currently include ophthalmic surgery as part of mandatory or voluntary surveillance of surgical site infections.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"} } , "answeringMemberConstituency" : {"_value" : "South Ribble"} , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"} , "dateOfAnswer" : {"_value" : "2019-05-15", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-05-15T16:24:36.63Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-05-07", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Hospitals: Infectious Diseases"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 20 March 2019 to Question 231466 on Hospitals: Infectious Diseases, whether work of Public Health England will also include as assessment of the effect of changes to ophthalmic surgical practice on trends in the level of risk of infection rates in hospitals.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"} } , "tablingMemberConstituency" : {"_value" : "Strangford"} , "tablingMemberPrinted" : [{"_value" : "Jim Shannon"} ], "uin" : "251326"} , {"_about" : "http://data.parliament.uk/resources/1124924", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1124924/answer", "answerText" : {"_value" : "

For the 2017/19 national tariff (which was set for two years), the prices for BZ91 were manually increased above the initially modelled level (based on 2014/15 reference costs) following feedback from the ophthalmology Expert Working Group (EWG). For 2019/20, the EWG recommended that the prices for BZ91 should not be increased and should remain as modelled (based on 2016/17 reference costs).<\/p>

The EWG also confirmed that minimally invasive glaucoma surgery (MIGS) and cataract activity are commonly done together and it would not usually be in the patient\u2019s best interest to do them separately. The EWG advised that BZ91 was appropriate for combined MIGS and cataract activity \u2013 a MIGS procedure plus a cataract procedure should not receive over twice as much as either procedure alone.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"} } , "answeringMemberConstituency" : {"_value" : "South Ribble"} , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"} , "dateOfAnswer" : {"_value" : "2019-05-15", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-05-15T16:43:32.397Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-05-07", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Ophthalmic Services"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 20 March 2019 to Question 231467 on Ophthalmic Services, whether he has made an assessment of the ability for clinicians to take into account patients\u2019 wishes for concomitant treatment in relation to potential restrictions of the 2019/2020 NHS Tariff.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"} } , "tablingMemberConstituency" : {"_value" : "Strangford"} , "tablingMemberPrinted" : [{"_value" : "Jim Shannon"} ], "uin" : "251327"} , {"_about" : "http://data.parliament.uk/resources/1124938", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1124938/answer", "answerText" : {"_value" : "

Public Health England and the Department for Environment, Food and Rural Affairs (Defra) are exploring whether social marketing can assist in awareness-raising about air pollution.<\/p>

The Joint Air Quality Unit (JAQU) is planning a national-level campaign to support Clean Air Zones (CAZ) from summer 2019. This will raise awareness of the risks presented by high concentrations of nitrogen dioxide (NO2) and the implementation of charging CAZ. It will also promote long-term behaviour change by encouraging the public to change travel habits and reduce NO2 emissions.<\/p>

The JAQU has also provided a CAZ communications toolkit to support local authorities in their local communications work. It contains key messages, frequently asked questions, useful statistics, infographics and other content to ensure a consistent approach is taken to raising awareness and to encourage drivers to consider alternative options in terms of travel and vehicle choice.<\/p>

Defra is developing a communication strategy on domestic combustion for launch before the next winter burning season.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"} } , "answeringMemberConstituency" : {"_value" : "South Ribble"} , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"} , "dateOfAnswer" : {"_value" : "2019-05-15", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-05-15T16:30:01.73Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-05-07", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Health Education: Air Pollution"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what progress his Department is making on producing a public information campaign to educate the general public on the health impacts of air pollution, particularly in instances of moderate or high pollution episodes.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1564", "label" : {"_value" : "Biography information for Angela Smith"} } , "tablingMemberConstituency" : {"_value" : "Penistone and Stocksbridge"} , "tablingMemberPrinted" : [{"_value" : "Angela Smith"} ], "uin" : "251250"} , {"_about" : "http://data.parliament.uk/resources/1124952", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1124952/answer", "answerText" : {"_value" : "

We remain committed to implementing fully the provisions within the Mental Health Units (Use of Force) Act 2018. We will work closely with key stakeholders in preparing the relevant statutory guidance and bring the legislation into force in due course.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"} } , "answeringMemberConstituency" : {"_value" : "Thurrock"} , "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"} , "dateOfAnswer" : {"_value" : "2019-05-15", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-05-15T16:10:40.887Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-05-07", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Mental Health Units (Use of Force) Act 2018"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what the timeframe is for bringing into force the provisions of the Mental Health Units (Use of Force) Act 2018.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4368", "label" : {"_value" : "Biography information for Neil Coyle"} } , "tablingMemberConstituency" : {"_value" : "Bermondsey and Old Southwark"} , "tablingMemberPrinted" : [{"_value" : "Neil Coyle"} ], "uin" : "251343"} ], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&max-ddpModified.=2019-10-16T20%3A15%3A56.062Z&AnsweringBody.=Department+of+Health+and+Social+Care&min-answer.questionFirstAnswered.=2019-05-15T12%3A39%3A20.147Z&dateTabled=2019-05-07&max-questionFirstAnswered.=2019-10-29T15%3A50%3A45.767Z", "page" : 0, "startIndex" : 1, "totalResults" : 35, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} }